Positive inotropic therapy: An update and new agents

Current Problems in Cardiology

Volumn 21, Issue 8, 1996, Pages 521-581

  Leier, Carl V ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030204143     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0146-2806(96)80002-8     Document Type: Review

References (255)

1. Binkley PF, Boudoulas H. Measurement of myocardial inotropy. In: Leier CV, editor. Cardiotonic drugs: a clinical review. New York: Marcel Dekker, 1991:5-62.
2. Bowditch HP. Uber die eigenthumlichkeiten der reizbarkeit welche die muskelfasern des herzens zeigen. Arb Physiol Aust 1871;6:139-76.
3. Sonnenblick EH. Force-velocity relations in mammalian heart muscle. Am J Physiol 1962;202:931-9.
4. Mitchell JH, Wallace AG, Skinner NS Jr. Intrinsic effects of heart rate on left ventricular performance. Am J Physiol 1963;205:41-8.
5. Covell JW, Ross J Jr, Taylor R, Sonnenblick EH, Braunwald E. The effects of increasing frequency of contraction on the force-velocity relation of the left ventricle. Cardiovasc Res 1967;1:2-8.
6. Mahler F, Yoran C, Ross J Jr. Inotropic effect of tachycardia and poststimulation potentiation in the conscious dog. Am J Physiol 1974;227:569-75.
7. Freeman GL, Little WC, O'Rourke RA. Influence of heart rate on left ventricular performance in conscious dogs. Circ Res 1987;61:455-64.
8. Feldman MD, Alderman JD, Aroesty JM, et al. Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy. J Clin Invest 1988;82:1661-9.
9. Mulieri LA, Hasenfuss G, Leavitt B, Allan PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation 1992;85:1743-50.
10. Ross J Jr, Miura T, Kambayashi M, Eising GP, Ryu KH. Adrenergic control of the force-frequency relation. Circulation 1995;92:2327-32.
11. Wilcken DEL, Charlier AA, Hoffman JIE, Buz A. Effects of alterations in aortic impedance on the performance of the ventricles. Circ Res 1964;14:283-93.
12. Pepine CJ, Nichols WW, Conti CR. Aortic input impedance in heart failure. Circulation 1978;58460-5.
13. O'Rourke MF, Yaginuma T, Avolio AP. Physiologic and pathophysiologic implications of ventricular/vascular coupling. Ann Biomed Eng 1984;12:119-34.
14. Laskey WK, Kussmaul WG, Martin JL, Kleaveland JP, Hirshfeld JW, Shroff S. Characteristics of vascular hydraulic load in patients with heart failure. Circulation 1985;72:61-71.
15. Binkley PF, VanFossen DB, Nunziata E, Unverferth DV, Leier CV. Influence of positive inotropic therapy on pulsatile hydraulic load and ventricular-vascular coupling in congestive heart failure. J Am Coll Cardiol 1990;15:1127-35.
16. Binkley PF, VanFossen DB, Leier CV. Contrasting effect of dopamine and dobutamine on pulsatile hydraulic load. Circulation 1988;78:II-104.
17. Binkley PF, VanFossen DB, Nunziata E, Leier CV. Accelerated arterial wave reflection with dopamine but not dobutamine in congestive heart failure. J Am Coll Cardiol 1989;13:247A.
18. Leier CV, Hammer DF, Unverferth DV. Endogenous positive inotropes. In: Leier CV, editor. Cardiotonic drugs: a clinical review. New York: Marcel Dekker, 1991:305-56.
19. Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995;92:262-7.
20. Moravec CS, Schluchter MD, Paranandi L, et al. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation 1990;82:1973-84.
21. Hattori Y, Nakaya H, Nishihira J, Kanno M. A dual-component positive inotropic effect of endothelin-1 in guinea pig left atria: a role of protein kinase C. J Pharmacol Exp Ther 1993;266:1202-12.
22. Franco-Cereceda A, Bentgsson L, Lundberg JM. Inotropic effects of calcitonin gene-related peptide, vasoactive intestinal polypeptide and somatostatin on human right atrium in vitro. Eur J Pharmacol 1987;134:69-76.
23. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
24. 1-receptor downregulation in heart failure. Circ Res 1986;59:297-309.
25. Colucci WB, Ludmer PL, Gauthier DF. Beta-adrenergic inotropic responsiveness of patients with heart failure. Circ Res 1987;61:I82-6.
26. Brown L, Lorenz B, Erdmann E. Reduced positive inotropic effects in diseased human ventricular myocardium. Cardiovasc Res 1986;20:516-20.
27. 2-adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989;35:295-303.
28. Leier CV, editor. Cardiotonic drugs: a clinical review. New York: Marcel Dekker, 1991.
29. Leier CV. Current status of nondigitalis positive inotropic drugs. Am J Cardiol 1992;69:120G-9G.
30. Leier CV, Binkley PF. Newer inotropic agents. In: McCall D, Rahimtoola SH, editors. Heart Failure. Florence, KY: Chapman and Hall, 1995:270-97.
31. Feldman AM. Classification of positive inotropic agents. J Am Coll Cardiol 1993;22:1223-7.
32. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation 1984;69:451-60.
33. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamics and neurohormonal effects of intravenous captopril and digoxin and their combination in patients with severe heart failure. J Am Coll Cardiol 1989;13:134-42.
34. Ferguson DW, Berg WJ, Sanders JS, Roach PF, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 1989;80:65-77.
35. Van Veldhuisen DJ, Brouwer J, Man in't Veld AJ, Dunselman PHJM, Boorsma F, Lie KI for the DIMT Study Group. Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. Am J Cardiol 1995;75:796-800.
36. Krum H, Bigger JT, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995;25:289-94.
37. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, et al. for the Dutch Ibopamine Multicenter trial (DIMT) Study Group. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal-modulation by digoxin and ibopamine. J Am Coll Cardiol 1995;26:983-90.
38. Goldsmith SR, Simon AB, Miller E. Effect of digitalis on norepinephrine kinetics in congestive heart failure. J Am Coll Cardiol 1992;20:858-63.
39. Covit AB, Schaer GL, Sealey JE, Laragh JH, Cody RJ. Suppression of the reninangiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med 1983;75:445-7.
40. Strickler JC, Kessler RH. Direct renal action of some digitalis steroids. J Clin Invest 1961;40:311-7.
41. Block KD, Zmir N, Lichstein D, Seidman CE, Seidman JG. Ouabain induces secretion of pro-atrial natriuretic factor in rat atrial cardiocytes. Am J Physiol 1988;255:E383-7.
42. Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic hormonal study. Am J Cardiol 1985;56:896-904.
43. Gheorghiade M, St. Clair J, St. Clair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987;9:849-57.
44. Cohn K, Selzer A, Kersh ES, Karpman LS, Goldschlager N. Variability of hemodynamic responses to acute digitalization in chronic cardiac failure due to cardiomyopathy and coronary artery disease. Am J Cardiol 1975;35:461-8.
45. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-44.
46. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R for Milrinone Trial Group. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83.
47. Davies RF, Beansland DS, Nadeau C, et al. for the Canadian Enalapril Versus Digoxin Study Group. Enalapril versus digoxin in patients with congestive heart failure. J Am Coll Cardiol 1991;18:1602-9.
48. Packer M, Gheorghiade M, Young JB, et al. for the RADIANCE study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1-7.
49. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993;22:955-62.
50. Sullivan M, Atwood JE, Myers J, et al. Increased exercise capacity after digoxin administration in patients with heart failure. J Am Coll Cardiol 1989;13:1138-43.
51. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995;92:1801-7.
52. Leier CV. Cardiotonic drugs. New York: Marcel Dekker, 1991.
53. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor downregulation and subsensitivity to agonist response. Circulation 1986;74:1290-302.
54. 1-adrenergic receptors in the failing human heart. Circulation 1993;87:454-63.
55. Binkley PF, Murray KD, Watson KM, Myerowitz PD, Leier CV. Dobutamine increases cardiac output of the total artificial heart: implications for vascular contribution of inotropic agents to augmented ventricular function. Circulation 1991;84:1210-5.
56. Binkley PF, VanFossen DB, Nunziata E, Unverferth DV, Leier CV. Influence of positive inotropic therapy on pulsatile hydraulic load and ventricular-vascular coupling in congestive heart failure. J Am Coll Cardiol 1990;15:1127-35.
57. Binkley PF, VanFossen DB, Haas GJ, Leier CV. Increased ventricular contractility is not sufficient for effective positive inotropic intervention. Am J Physiol (in press).
58. Keren G, Laniado S, Sonnenblick EH, Lejemtel TH. Dynamics of functional mitral regurgitation during dobutamine therapy in patients with severe congestive heart failure. Am Heart J 1989;118:748-54.
59. Ferrario M, Poli A, Previtali M, et al. Hemodynamics of volume loading compared with dobutamine in severe right ventricular infarction. Am J Cardiol 1994;74:329-33.
60. Magorien RD, Unverferth DV, Brown GP, Leier CV. Dobutamine and hydralazine: comparative influence of positive inotropy and vasodilation on coronary blood flow and myocardial energetics in nonischemic congestive heart failure. J Am Coll Cardiol 1983;1:499-505.
61. Dubois-Rande JL, Merlet P, Duval-Moulin AM, et al. Coronary vasodilating action of dobutamine in patients with idiopathic dilated cardiomyopathy. Am Heart J 1983;105:176-81.
62. Unverferth DV, Magorien RD, Lewis RP, Leier CV. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 1983;105:176-81.
63. Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe heart failure. Circulation 1977;56:468-72.
64. Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980;100:622-30.
65. Leier CV, Unverferth DV Medical therapy of end-stage congestive and ischemic cardiomyopathy. In: Cardiovascular clinics - cardiomyopathy: clinical presentation, differential diagnosis, and management. Philadelphia: Davis Publishing, 1988: 24-51.
66. Miller LW, Merkle EJ, Herrmann V. Outpatient dobutamine for end-stage congestive heart failure. Crit Care Med 1990;18:S30-3.
67. Leier CV, Huss P, Lewis RP, Unverferth DV. Drug-induced conditioning in congestive heart failure. Circulation 1982;65:1382-7.
68. Applefeld MM, Newman KA, Sutton FJ, et al. Outpatient dobutamine and dopamine infusions in the management of chronic heart failure. Am Heart J 1987;114:589-95.
69. Van den Brande P, Van Mieghem W, Demedts M. Intermittent dobutamine infusions in severe chronic heart failure in elderly patients. Gerontology 1990;36:49-54.
70. Dies F, Krell MH, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [abstract]. Circulation 1986;74:II-38.
71. Unverferth DV, Magorien RD, Altschuld R, Kolibash AJ, Lewis RP, Leier CV. The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1983;106: 29-43.
72. Unverferth DV, Leier CV, Magorien RD, et al. Improvement of human myocardial mitochondria after dobutamine: a quantitative ultrastructural study. J Pharmacol Exp Ther 1980;215:527-33.
73. Sullivan MJ, Binkley PF, Unverferth DV, et al. Prevention of bedrest-induced physical deconditioning by daily dobutamine infusions: implications for drug-induced physical conditioning. J Clin Invest 1985;76:1632-42.
74. Dupuis J, Lalonde G, Lebeau R, Rouleau JL. Sustained beneficial effects of a seventy-two hour intravenous infusion of nitroglycerin in patients with severe chronic congestive heart failure. Am Heart J 1990;120:625-37.
75. Marwick T, D'Hondt AM, Baudhuin T, Willemart B, Wijns W, Detry JM, Melin J. Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? J Am Coll Cardiol 1993;22:159-67.
76. Afridi I, Quinones MA, Zoghbi WA, Cheirif J. Dobutamine stress echocardiography: sensitivity, specificity, and predictive value for future cardiac events. Am Heart J 1994;127:1510-5.
77. Pennell DJ, Underwood SR, Swanton RH, Walker JM, Ell PJ. Dobutamine thallium myocardial perfusion tomography. J Am Coll Cardiol 1991;18:1471-9.
78. Van Rugge FP, van der Wall EE, Spanjersberg SJ, et al. Magnetic resonance imaging during dobutamine stress for detection and localization of coronary artery disease. Circulation 1994;90:127-38.
79. Young M, Pan W, Wiesner J, et al. Characterization of arbutamine: a novel catecholamine stress agent for diagnosis of coronary artery disease. Drug Dev Res 1994;32:19-28.
80. Hammond HK, McKirnan MD. Effects of dobutamine and arbutamine on regional myocardial function in a porcine model of myocardial ischemia. J Am Coll Cardiol 1994;23:475-82.
81. Dennis CA, Pool PE, Perrins EJ, et al. for the International Arbutamine Study Group. Stress testing with closed-loop arbutamine as an alternative to exercise. J Am Coll Cardiol 1995;26:1151-8.
82. Kiat H, Iskandrian AS, Villegas BJ, Starling MR, Verman DS for the International Arbutamine Study Group. Arbutamine stress thallium-201 single-photon emission computed tomography using a computerized closed-loop delivery system. J Am Coll Cardiol 1995;26:1159-67.
83. Cohen JL, Chan KL, Jaarsma W, et al. for the International Arbutamine Study Group. Arbutamine echocardiography: efficacy and safety of a new pharmacologic stress agent to induce myocardial ischemia and detect coronary artery disease. J Am Coll Cardiol 1995;25:1168-75.
84. 2-adrenoceptors. Br J Pharmacol 1985;85:599-608.
85. Brown RA, Farmer JB, Hall JC, Humphries RG, O'Connor SE, Smith GW. The effects of dopexamine on the cardiovascular system of the dog. Br J Pharmacol 1985;85:609-19.
86. Leier CV, Binkley PR, Carpenter J, Randolph PH, Unverferth DV Cardiovascular pharmacology of dopexamine in low output congestive heart failure. Am J Cardiol 1988;62:94-9.
87. Dawson JR, Thompson DS, Signy M, et al. Acute hemodynamic and metabolic effects of dopexamine, a new dopaminergic receptor agonist, in patients with chronic heart failure. Br Heart J 1985;54:313-20.
88. Tan LB, Littler WA, Murray RG. Beneficial hemodynamic effects of intravenous dopexamine in patients with low-output heart failure. J Cardiovasc Pharmacol 1987;10:280-6.
89. Baumann G, Felix SV, Filcek SAL. Usefulness of dopexamine hydrochloride versus dobutamine in chronic congestive heart failure and effects of hemodynamics and urine output. Am J Cardiol 1990;65:748-54.
90. Jamison M, Widerhorn J, Weber L, et al. Central and renal hemodynamic effects of a new agonist at peripheral dopamine- and beta-2 adrenoreceptors (dopexamine) in patients with heart failure. Am Heart J 1989;117:607-14.
91. Murphy JJ, Hampton JR. Failure of dopexamine to maintain hemodynamic improvement in patients with chronic heart failure. Br Heart J 1988;60:45-9.
92. 2-adrenoceptor agonist dopexamine in end-stage congestive heart failure. Am J Cardiol 1990;65:395-6.
93. Leier CV, Binkley PF, Cody RJ. Alpha-adrenergic component of the sympathetic nervous system in congestive heart failure. Circulation 1990;82:I-68-I-76.
94. 1-adrenoceptors mediate positive inotropic effect and changes in phosphatidylinositol metabolism. Circ Res 1991;68:1179-90.
95. Terzic A, Vogel SM. On the mechanism of the positive inotropic action of the alpha adrenoceptor agonist, phenylephrine, in isolated rat left atria. J Pharmacol Exp Ther 1991;257:520-9.
96. 1-adrenoceptor stimulation in rat cardiac myocytes. Circ Res 1992;71:673-88.
97. Binkley PF, Lewe RF, Unverferth DV, Leier CV Preservation of end-systolic pressure/ end-systolic dimension relation following pindolol in congestive heart failure. Am Heart J 1988;115:1245-50.
98. Binkley PF, Lewe RF, Lima J, Unverferth DV, Leier CV. Neurohumoral profile in congestive heart failure: response to β-blockade. J Lab Clin Med 1988;111:393-8.
99. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
100. Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest 1984;74: 212-23.
101. Bauman G, Felix S, Sattelberger U, Kelin G. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy in a comparative study with dobutamine and sodium nitroprusside. J Cardiovasc Pharmacol 1990;16:93-100.
102. Hubbard JW, Conway PG, Nordstron LC, et al. Cardiac adenylate cyclase activity, positive chronotropic and inotropic effects of forskolin analogs with either low, medium or high binding site affinity. J Pharmacol Exp Ther 1991;256:621-7.
103. Mori M, Takeuchi M, Takaoka H, Hata K, Hayashi Y, Yokoyama M. Effect of NKH477, a new water-soluble forskolin derivative, on arterial-ventricular coupling and mechanical energy transduction in patients with left ventricular systolic dysfunction: comparison with dobutamine. J Cardiovasc Pharmacol 1994;24: 310-6.
104. Wilmshurst PT, Thompson DS, Jenkins BS, Coltart DJ, Webb-Peploe MM. Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. Br Heart J 1983;49:77-82.
105. Hermiller JB, Leithe ME, Magorien RD, Unverferth DV, Leier CV. Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug. J Pharmacol Exp Ther 1984;229:319-26.
106. Wilmshurst PT, Thompson DS, Juul SM, Jenkins BS, Coltart DJ, Webb-Peploe MM. Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. Br Heart J 1984;52:38-48.
107. Marcus RH, Raw K, Patel J, Mitha A, Sareli P. Comparison of intravenous amrinone and dobutamine in congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1990;66:1107-12.
108. Edelson J, LeJemtel TH, Alousi AA, et al. Relationship between plasma amrinone concentration and cardiac index. Clin Pharmacol Ther 1981;29:723-8.
109. Maisel AS, Wright CM, Carter SM, et al. Tachyphylaxis with amrinone therapy: association with sequestration and downregulation of lymphocyte beta-adrenergic receptors. Ann Intern Med 1989;110:195-201.
110. Butterworth JF, Royster RL, Prielipp RC, Lawless ST, Wallenhaupt SL. Amrinone in cardiac surgical patients with left ventricular dysfunction: a prospective randomized placebo-controlled trial. Chest 1993;104:1660-7.
111. Leier CV, Dalpiaz K, Huss P, et al. Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. Am J Cardiol 1983;52:304-8.
112. Massie B, Bourassa M, DiBianco R, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 1985;71:963-71.
113. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J Clin Invest 1985;75:643-9.
114. Cody RJ, Muller FB, Kubo SH, Rutman H, Leonard D. Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure. Circulation 1986;73:124-9.
115. Biddle TL, Benotti JR, Creager MA, et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol 1987;59:1345-50.
116. Grose R, Strain J, Greenberg M, LeJemtel TH. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol 1986;7:1107-13.
117. Benotti JR, Lesko LJ, McCue JE, Alpert JS. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. Am J Cardiol 1985;56:685-9.
118. Kubo SH, Cody RJ, Chatterjee K, Simonton C, Rutman H, Leonard D. Acute dose range study of milrinone in congestive heart failure. Am J Cardiol 1985;55:726-30.
119. Konstam MA, Cody RJ. Short-term use of intravenous milrinone for heart failure. Am J Cardiol 1995;75:822-6.
120. DiBianco R, Shabetai R, Kostik W, Moran J, Schlant R, Wright R, for the Milrinone Trial Group. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83.
121. Packer M, Carber JR, Rodeheffer RJ, et al. for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
122. Shah PK, Amin DK, Hulse S, Shellock F, Swan HJC. Inotropic therapy for refractory congestive heart failure with oral enoximone (MDL 17,043): poor long-term results despite early hemodynamic and clinical improvement. Circulation 1985;71: 326-31.
123. Leier CV, Binkley PF, Starling RC, Huss-Randolph P. Disparity between improvement in left ventricular function and changes in clinical status and exercise capacity during enoximone therapy. Am Heart J 1989;117:1092-8.
124. Uretsky BF, Jessup M, Konstam M, et al. for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared to placebo. Circulation 1990;82:774-80.
125. max) in isolated contractile structures from mammalian heart muscle. Arzneimittelforschung Res 1981;31:188-91.
126. 2+ binding and ATPase activity of dog cardiac myofibrils by AR-L 115 BS, a novel cardiotonic agent. Circ Res 1982;51:290-4.
127. ++ as an inotropic mechanism. Circulation 1986;73(suppl III):III-85-98.
128. Pan BS, Solaro RJ. Calcium binding properties of troponin C in detergent skinned heart muscle fibers. J Biol Chem 1987;262:7339-49.
129. Reugg JC, Morano I. Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol 1989;14(suppl 3):S20-3.
130. Muller-Beckmann B, Freund P, Honerjager P, Kling L, Ruegg JC. In vitro investigations on a new positive inotropic vasodilating agent (BM 14.478) that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity. J Cardiovasc Pharmacol 1988;11:8-16.
131. Hajjar RJ, Gwathmey JK, Briggs GM, Morgan JP. Differential effect of DPI 201-106 on the sensitivity of the myofilaments to CA in intact and skinned trabeculae from control and myopathic human hearts. J Clin Invest 1988;82:1578-84.
132. ++ sensitivity of the contractile system by MCI-154, a novel cardiotonic agent, in chemically skinned fibers from the guinea pig papillary muscles. Eur J Pharmacol 1987;134:229-31.
133. Fujino K, Sperelakis N, Solaro RJ. Differential effects of stereoisomers of pimobendan on myofibrillar Ca-sensitization and cardiac inotropic effects. J Pharmacol Exp Ther 1988;247:519-23.
134. Lues I, Siegel R, Harting J. Effect of isomazole on the responsiveness to calcium of the contractile elements in skinned cardiac muscle fibers of various species. Eur J Pharmacol 1988;146:145-53.
135. ++ sensitivity and economization of the myocardial contractile process. J Mol Cell Cardiol 1983;15(suppl 1):244-51.
136. 2+ transient in rat myocardium. J Mol Cell Cardiol 1991;23:325-31.
137. Kawabata Y, Endoh M. Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res 1993;72:597-606.
138. Nankervis R, Lues I, Brown L. Calcium sensitization as a positive inotropic mechanism in diseased rat and human heart. J Cardiovasc Pharmacol 1994;24: 612-7.
139. Gambassi G, Capogrossi MC, Klockow M, Lakatta EG. Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes. Am J Physiol 1993;264:H728-38.
140. Endoh M. The effects of various drugs on the myocardial inotropic response. Gen Pharmacol 1995;26:1-31.
141. Hgashiyama A, Watkins MW, Chen Z, LeWinter ML. Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts. Circulation 1995:92:3094-104.
142. Allen DG, Kentish JC. Calcium concentration in the myoplasm of skinned ferret ventricular muscle following changes in muscle length. J Physiol (Lond) 1988;407:489-94.
143. Doggrell S, Hoey A, Brown L. Ion channel modulators as potential positive inotropic compounds for treatment of heart failure. Clin Exp Pharmacol Physiol 1994;21:833-43.
144. Schwinger RHG, Bohm M, Mittmann C, Rosee KL, Erdmann E. Evidence for a sustained effectiveness of sodium-channel activators in failing human myocardium. J Moll Cell Cardiol 1991;23:461-71.
145. Buggisch D, Isenberg G, Ravens U, Scholtysik G. The role of sodium channels in the effects of the cardiotonic compound DP 201-206 on contractility and membrane potentials in isolated mammalian heart preparations. Eur J Pharmacol 1985;118: 303-11.
146. Ravens U, Wettwer E, Pfeifer T, Himmel H, Armah B. Characterization of the effects of the new inotropic agent BDF 9148 in isolated papillary muscles and myocytes of the guinea-pig heart. Br J Pharmacol 1991;104:1019-23.
147. Gwathmey JK, Slawsky M, Briggs GM, Morgan JP. Role of intracellular sodium in the regulation of intracellular calcium and contractility: effects of DPI 201-106 on excitation-contraction coupling in human ventricular myocardium. J Clin Invest 1988;82:1592-605.
148. Bohm M, Diet F, Kemkis B, Wankerl M, Erdmann E. Inotropic response to DPI 201-106 in the failing human heart. Br J Pharmacol 1989;98:275-83.
149. Ozaki T, Uematsu T, Nagashima S, Nishimoto M, Nakashima M. Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: a comparative study with dobutamine. Naunyn Schmiedebergs Arch Pharmacol 1991;344:478-87.
150. Amos GJ, Ravens U. The inotropic agents DPI 201-106 and BDF 9148 differentially affect potassium currents of guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 1994;350:426-33.
151. Hoey A, Amos GJ, Ravens U. Comparison of the action potential prolonging and positive inotropic activity of DPI 201-106 and BDF 9148 in human ventricular myocardium. J Mol Cell Cardiol 1994;26:985-94.
152. Brasch H, Iven H. Inotropic and electrophysiological effects of BDF 9148, a congener of DPI 201-106, in guinea-pig atria and papillary muscles. Br J Pharmacol 1991;103:1939-45.
153. 3H]ouabain binding in guinea pig heart. J Cardiovasc Pharmacol 1991;18:182-9.
154. +- channel activators increase cardiac glycoside sensitivity in failing human myocardium. J Cardiovasc Pharmacol 1992;19:554-61.
155. Hoey A, Lehmkuhl A, Sadony V, Ravens U. Inotropic actions of BDF 9148 and DPI 201-106 and their enantiomers in guinea-pig, rat and human atria. Eur J Pharmacol 1993;231:477-80.
156. Gerard JL, Berdeaux A, Giudicelli IF. Cardiac and hemodynamic profile of the new cardiotonic agent, DPI 201-106, in the conscious dog. Eur J Pharmacol 1989;165: 39-49.
157. Gerard JL, Berdeaux A, Giudicelli JF. Cardiac and hemodynamic effects of S(-)-and R(+)-DPI 201-106 and of racemic DPI 201-106 in conscious dogs. Eur J Pharmacol 1990;184:321-3.
158. Walker MJ, Tuna IC, Gornick CC, et al. Cardiac electrophysiologic effects of orally administered DPI 201-106 in conscious canines: effects of pharmacologic autonomic blockade or cardiac transplantation. J Cardiovasc Pharmacol 1989;14:381-8.
159. Scholtysik G, Williams FM. Antiarrhythmic effects of DPI 201-106. Br J Pharmacol 1986;89:287-92.
160. Butrous GS, Debbas NM, Erwin J, et al. Clinical cardiac electrophysiologic evaluation of the positive inotropic agent, DPI 201-106. Eur Heart J 1988;9:489-97.
161. Kostis JB, Lacy CR, Raia JJ, Dworkin JH, Warner RG, Casazza LA. DPI 201-106 for severe congestive heart failure. Am J Cardiol 1987;60:1334-9.
162. Baumgart D, Ehring T, Krajear M, Skyschally A, Heusch G. Characterization of the inotropic and arrhythmogenic action of the sodium channel activator BDF 9148: a comparison to its S-enantiomer BDF 9196, to its congener DPI 201-106, to norepinephrine, and to ouabain. Basic Res Cardiol 1994;89:61-79.
163. Bohm M, La Rosee K, Schmidt U, Schulz C, Schwinger RH, Erdmann E. Force-frequency relationship and inotropic stimulation in the nonfailing and failing human myocardium: implications for the medical treatment of heart failure. Clin Invest 1992;70:421-5.
164. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995;92:2540-9.
165. Verdouw PD, Hartog JM, Duncker DJ, Roth W, Saxena PR. Cardiovascular profile of pimobendan, a benzimidazole-pyridazone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986;126:21-30.
166. Pouleur H, Gurne O, Hanet C, Balasim H, van Mechelen H, Charlier AA. Effects of pimobendan (UD-CG115) on the contractile function of the normal and "postischemic" canine myocardium. J Cardiovasc Pharmacol 1988;11:100-6.
167. Van der Giessen WJ, van Woerkens LJ, Duncker DJ, Roelandt JR, Verdouw PD. Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure. J Cardiovasc Pharmacol 1989;14:653-8.
168. Fujimoto S, Matsuda T. Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties on isolated arteries and veins of rats. J Pharmacol Exp Ther 1990;252:1304-11.
169. Hagemeijer F, Brand HJ, van Mechelen R. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989;63:571-6.
170. Hagemeijer F, Brand HJ, Roth W. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. J
171. Walter M, Liebens I, Goethals H, Renard M, Dresse A, Bernard R. Pimobendan (UD-CG 115 BS) in the treatment of severe congestive heart failure. Br J Clin Pharmacol 1988;25:323-9.
172. Hasenfuss G, Holubarsch C, Heiss HW, Just H. Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Am Heart J 1989;118:512-9.
173. Renard M, Walter M, Liebens I, Dresse A, Bernard R. Pimobendan (UD-CG 115 BS) in chronic congestive heart failure. Chest 1988;93:1159-64.
174. Remme WJ, Kruijssen DA, van Hoogenhuyze DC, et al. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. J Cardiovasc Pharmacol 1994;24:730-9.
175. Lee JA, Ruegg JC, Allen DC. Effects of pimobendan, a novel inotropic agent, on intracellular calcium and tension in isolated ferret ventricular muscle. Clin Sci 1989;76:609-18.
176. Bohm M, Morano I, Pieske B, et al. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 1991;68:689-701.
177. 2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 1991;68:689-701.
178. Endoh M, Shibasaki T, Satoh H, Norota I, Ishihata A. Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG212 CL in canine ventricular myocardium. J Cardiovasc Pharmacol 1991;17:365-75.
179. Baumann G, Ningel K, Permanetter B. Clinical efficacy of pimobendan (UD-CG115BS) in patients with chronic congestive heart failure. J Cardiovasc Pharmacol 1989;14:(suppl 2):S23-30.
180. Hata K, Goto Y, Futaki S, Ohgoshi Y, Yaku H, Kavaguchi O. Mechanoenergetic effects of pimobendan in canine left ventricles: comparison with dobutamine. Circulation 1992;86:1291-301.
181. Katz SD, Kubo SH, Jessup M, et al. A multicenter, randomized double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 1992;123:95-103.
182. Asanoi H, Ishizaka S, Kameyama T, Ishise H, Sasayama S. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 1994;23:268-74.
183. Binkley PF, Shaffer PB, Ryan JM, Leier CV. Augmentation of diastolic function with phosphodiesterase inhibition in congestive heart failure. J Lab Clin Med 1989;114:266-71.
184. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial: The Pimobendan Multicenter Research Group. Circulation 1992;85:942-9.
185. Remme WJ, Krayenbubl HP, Baumann G, et al. Long-term efficacy and safety of pimobendan in moderate heart failure: a double-blind parallel 6-month comparison with enalapril: The Pimobendan-Enalapril Study Group. Eur Heart J 1994;15: 947-56.
186. Just H, Hjalmarsson A, Remme WJ, et al. on behalf of the Pimobendan in Congestive Heart Failure (PICO) Investigators. Pimobendan in congestive heart failure: results of the PICO trial [abstract]. Circulation 1995;92:I-722.
187. Van Meel JC, Mauz AB, Wienen W, Diederen W. Pimobendan increases survival of cardiomyopathic hamsters. J Cardiovasc Pharmacol 1989;13:508-9.
188. Thormann J, Kramer W, Schlepper M. Changes of hemodynamics, coronary flow and myocardial energy metabolism in patients with coronary artery disease after the application of the new cardiotonic agent AR-L 115. Am Heart J 1982;104: 1294-302.
189. Renard M, Jacobs P, Dechamps P, Dresse A, Bernard R. Hemodynamic and clinical response to three-day infusion of sulmazol (AR-L 115 BS) in severe congestive heart failure. Chest 1983;84:408-13.
190. Thormann J, Schlepper M, Kramer W, Gottwik M, Kindler M. Effects of AR-L 115 BS (sulmazol), a new cardiotonic agent, in coronary artery disease: improved ventricular wall motion, increased pump function and abolition of pacing-induced ischemia. J Am Coll Cardiol 1983;2:332-7.
191. Barkenboom GM, Sobolski JC, Depelchin PE, Contu E, Dieudonne PJ, Degre SG. Clinical and hemodynamic observations on orally administered sulmazol (AR-L 115 BS) in refractory heart failure. Cardiology 1984;71:323-30.
192. Zrenner E, Kramer W, Bopp M, Schlepper M. Rapid effects on colour vision, following intravenous injection of a new, non-glycoside positive inotropic substance (AR-L115BS). Doc Ophthalmol 1982;33:493-507.
193. Voelker W, Mauser M, Preisack M, Karsch KR. Acute hemodynamic effects of adibendan, a new phosphodiesterase inhibitor, for congestive heart failure. Am J Cardiol 1989;64:390-3.
194. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.
195. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. J Biol Chem 1994;269:28584-90.
196. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-13.
197. Haikala H, Nissinen E, Etemadzadah E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995;25:794-801.
198. Pagel PS, Harkin CP, Hethick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 1994;81:974-97.
199. Harkin CP, Pagel PS, Tessmer JP, Warltier DC. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 1995;26:179-88.
200. Lilleberg J, Antila S, Karlsson M, Nieminen MS, Pentkainen PF. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Clin Pharmacol Ther 1994;56:554-63.
201. Lilleberg J, Sundberg S, Hayha M, Akkila J, Nieminen MS. Hemodynamic dose-efficacy of levosimendan in health volunteers. Eur J Clin Pharmcol 1994;47:267-74.
202. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995;75:1061-6.
203. Tominaga M, Yo E, Ogawa H. Studies on positive inotropic agents: 1. Synthesis of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-L-piperazinyl]-2(1H)-quinolinone and related compounds. Chem Pharm Bull (Tokyo) 1984;32:2100-10.
204. Yanagisawa T, Endoh M, Taira N. Involvement of cyclic AMP in the positive inotropic effect of OPC 8212, a new cardiotonic agent, on the canine ventricular muscle. Jpn J Pharmacol 1984;36:379-88.
205. Takeya K, Yajima M, Kobayashi-Ando S, Ando H. Positive inotropic effect of (3,4-dihydro-6-[4-(3,4-dimethoxybenzyl)-L-piperazinyl]-2(1H)-quinolinone (OPC 8212) and mechanism of action in guinea pig ventricular myocardium. Arzneimittelforsch Drug Res 1984;34:364-70.
206. Lathrop DA, Schwartz A. Evidence for possible increase of sodium channel open time and involvement of Na/Ca exchange by a new positive inotropic drug: OPC 8212. Eur J Pharmacol 1985;117:391-2.
207. Iijima T, Taira N. Membrane current changes responsible for the positive inotropic effect of OPC 8212, a new positive inotropic agent, in single cells of the guinea pig heart. J Pharmacol Exp Ther 1987;240:657-62.
208. Rapundalo ST, Lathrop DA, Harrison SA, Beavo J, Schwartz A. Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212. Naunyn Schmiedebergs Arch Pharmacol 1988;338:692-8.
209. 2+ channels in ventricular myocytes of guinea pig. J Cardiovasc Pharmacol 1989;13:812-9.
210. Lathrop DA, Nanasi PP, Schwartz A, Varro A. Ionic basis for OPC 8212-induced increase in action potential duration in isolated rabbit, guinea pig, and human ventricular myocytes. Eur J Pharmacol 1993;240:127-37.
211. Lee JK, Kodama I, Suzuki R, Kamiya K, Toyama J. Low doses of vesnarinone decrease both potassium and calcium currents in ventricular cells [abstract]. Circulation 1995;92:I-603.
212. Lathrop DA, Varro A, Schwartz A. Rate-dependent electrophysiological effects of OPC 8212: comparison to sotalol. Eur J Pharmacol 1989;164:487-96.
213. Hashimoto K, Mitsuhashi H. Effects of OPC 8212, a new positive inotropic agent, on canine ventricular arrhythmias. Br J Pharmacol 1986;88:915-21.
214. Yanagisawa T, Ishii K, Taira N. Antitachycardic effect of OPC 8212, a novel cardiotonic agent, on tachycardic responses of guinea pig isolated right atria to isoproterenol and histamine. J Cardiovasc Pharmacol 1987;10:47-54.
215. Kumakura T, Takase K, Terada N, Gelfand EW. Vesnarinone inhibits nucleoside and nucleobase transport. Life Sci 1995;57:PL75-81.
216. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955-8.
217. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone: suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest 1994;94:1212-7.
218. Hattori Y, So S, Hattori S, Kasai K, Shimoda S. Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardiovasc Res 1995;30:187-92.
219. Maruyama I, Maruyama Y, Nakajima T, et al. Vesnarinone inhibits production of HIV-1 in cultured cells. Biochem Biophys Res Commun 1993;195:1264-71.
220. Busch FW, Tillmann A, Becker EW, et al. The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dyhydro-6-[4-(3,4-dimethoxybenzoyl)-L-piperazinyl]-2(1H)-quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes. Eur J Clin Pharmacol 1992;42:629-33.
221. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323: 236-41.
222. Hegewish S, Weh H-J, Hossfeld DK. TNF-induced cardiomyopathy. Lancet 1990;2:294-5.
223. Hocking DC, Phillips PG, Ferro TJ, Johnson A. Mechanisms of pulmonary edema induced by tumor necrosis factor-α. Circ Res 1990;67:68-77.
224. Finkel MS, Oddis CV, Jacobi TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
225. Yamashita S, Hosokawa T, Kojima M, Mori T, Yabuuchi Y. In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-L-piperazinyl]-2(1H)-quinolinone (OPC-8212), a novel positive inotropic drug, in various animals. Arzneimittelforsch Drug Res 1984;34:342-6.
226. Grupp G, Grupp IL, Newman G, Schwartz A. Effects of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-L-piperazinyl]-2(1H)-quinolinone (OPC-8212) and its solvent sulfolane on isolated heart preparation of the rat, guinea pig, and dog. Arzneimittelforsch Drug Res 1984;34:359-63.
227. Hori M, Inoue M, Tamai J, et al. Beneficial effect of OPC-8212 (3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-L-piperazinyl]-2(1H)-quinolinone) on myocardial oxygen consumption in dogs with ischemic heart failure. Jpn Circ J 1986;50:659-66.
228. Miyazaki S, Sasayama S, Nakamura Y, Kihara Y, Susawa T, Kawai C. Acute hemodynamic effects of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzyl)-I-piperazinyl]-2(1H)-quinolinone (OPC 8212), in conscious and anesthetized dogs. J Cardiovasc Pharmacol 1986;8:14-20.
229. Yanagisawa T, Endoh M, Taira N. Involvement of cyclic AMP in the positive inotropic effect of OPC 8212, a new cardiotonic agent, on the canine ventricular muscle. Jpn J Pharmacol 1984;36:379-88.
230. Asanoi H, Sasayama S, Iuchi K, Kameyama T. Acute hemodynamic effects of a new agent (OPC 8212) in patients with congestive heart failure. J Am Coll Cardiol 1987;9:865-71.
231. Sasayama S, Inoue M, Asanoi H, et al. Acute hemodynamic effects of a new inotropic agent, OPC 8212, on severe congestive heart failure. Heart Vessels 1986;2:23-8.
232. Nanto S, Kodama K, Kimura Y, et al. Effect of OPC-8212 (2(1H)-quinolinone), a new inotropic agent, on myocardial energy metabolism in patients with coronary heart disease. Jpn Circ J 1988;52:155-61.
233. Ohnishi A, Ishizaki T. Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycosidic, inotropic agent. J Clin Pharmacol 1988;28:719-26.
234. Inoue M, Kim B-H, Hori M, et al. Oral OPC 8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity. Heart Vessels 1986;2:166-71.
235. Feldman AM, Becker LC, Llewellyn MP Baughman KL. Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure. Am Heart J 1988;116:771-7.
236. Kubo SH, Rector TS, Strobeck JE, Cohn JN. OPC 8212 in the treatment of congestive heart failure: results of a pilot study. Cardiovasc Drug Ther 1988;2:653-60.
237. Asanoi H, Sasayama S, KameyamaT, Ishizaka S, Iuchi K. Sustained inotropic effects of a new cardiotonic agent, OPC 8212, in patients with chronic heart failure. Clin Cardiol 1989;12:133-8.
238. OPC 8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC 8212 in patients with mild chronic heart failure. Cardiovasc Drug Ther 1990;4:419-26.
239. Feldman AM, Baughman KL, Lee WK, et al. Usefulness of OPC 8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1991;68:1203-10.
240. Feldman AM, Bristow MR, Parmley WW, et al. for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.
241. Bertolet BD, White BG, Pepine CJ. Neutropenia occurring during treatment with vesnarinone (OPC-8212). Am J Cardiol 1994;74:968-70.
242. Uetrecht JP, Zahid N, Whitfield D. Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. J Pharmacol Exp Ther 1994;270:865-72.
243. Fujioka T, Teramoto S, Mori T, et al. Novel positive inotropic agents: synthesis and biological activities of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives. J Med Chem 1992;35:3607-12.
244. Wu Z, Awaji T, Abe H, Motomura S, Hashimoto K. Effects of OPC-18790, a new positive inotropic agent, on canine ventricular arrhythmias. Jpn J Pharmacol 1993;63:399-404.
245. Hosokawa T, Mori T, Fujiki H, et al. Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action. Heart Vessels 1992;7:66-75.
246. Endoh M, Kawabata Y, Katano Y, Norota I. Effects of a novel cardiotonic agent (±)-6[3-(3,4-dimethoxybenzyl-amino)-2-hydroxypropoxy]-2(1H)-quinolinone (OPC-18790) on contractile force, cyclic AMP level, and aequorin light transients in dog ventricular myocardium. J Cardiovasc Pharmacol 1994;23:723-30.
247. Ohnishi A, Toyoki T, Ohno T, et al. Pharmacokinetics and pharmacodynamics of intravenous OPC-18790 in humans: a novel nonglycosidic inotropic agent. J Clin Pharmacol 1994;34:176-83.
248. Hoit DB, Burwig S, Eppert D, Bhat G, Walsh RA. Effects of a novel inotropic agent (OPC-18790) on systolic and diastolic function in patients with severe heart failure. Am Heart J 1994;128:1156-63.
249. Abraham WT, Lowes BD, White M, et al. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. J Card Failure 1995;1:57-62.
250. Feldman MD, Pak PH, Wu CC, et al. Acute cardiovascular effects of OPC-18790 in patients with congestive heart failure: time- and dose-dependence analysis based on pressure-volume relations. Circulation 1996;93:474-83.
251. 31P-MRS study. Cardiovasc Res 1995;30:299-306.
252. Wu Z, Awaji T, Abe H, Motomura S, Hashimoto K. Effects of OPC-18790, a new positive inotropic agent, on canine ventricular arrhythmias. Jpn J Pharmacol 1993;63:399-404.
253. Furukawa Y, Akahane K, Haniuda M, Chiba S. Positive inotropic and negative chronotropic effects of OPC 8490, a newly developed cardiotonic, in isolated blood-perfused canine heart preparations. Jpn Heart J 1989;30:387-98.
254. Momose Y, Sasayama S. Effect of OPC-8490 on the membrane potentials and membrane currents of single guinea-pig myocytes. Cardiovasc Drugs Ther 1990;4:713-8.
255. Focaccio A, Peeters G, Movsesian M, Roden R, Eki Y, Krall J, Bristow MR. Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation 1996;93:817-25.